GlobeNewswire Inc | Jul 26, 2021 07:00AM EDT

July 26, 2021

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the company will be presenting at the upcoming 41st Annual Canaccord Genuity Virtual Global Growth Conference.

Renalytixs management is scheduled to present at the Canaccord Genuity Global Growth Conference on Wednesday, August 11 at 2:30pm EDT. Interested parties may access a live and archived webcast of the presentations on the Investors section of the company website at investors.renalytix.com.

For further information, please contact:

UK Investor Contact:

Walbrook PRLimited Tel: 020 7933 8780 orrenalytix@walbrookpr.comPaul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303

US Investor Contact:

Gilmartin Group investors@renalytix.comCarrie Mendivil / Mary Kate McDonough 415-937-5405

About RenalytixRenalytix is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Renalytix's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytix.com.